Head-To-Head Comparison: Fractyl Health (NASDAQ:GUTS) and AnaptysBio (NASDAQ:ANAB)

Fractyl Health (NASDAQ:GUTS) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Volatility & Risk

Fractyl Health has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Fractyl Health and AnaptysBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1	1	3	0	2.40
AnaptysBio	1	3	13	0	2.71

Fractyl Health presently has a consensus price target of $50.25, suggesting a potential upside of 4,552.78%. AnaptysBio has a consensus price target of $77.79, suggesting a potential upside of 59.63%. Given Fractyl Health’s higher possible upside, equities research analysts clearly believe Fractyl Health is more favorable than AnaptysBio.

Profitability

This table compares Fractyl Health and AnaptysBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
AnaptysBio	82.37%	112.00%	2.20%

Valuation & Earnings

This table compares Fractyl Health and AnaptysBio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90,000.00	159.12	-$140.95 million	($10.56)	-0.10
AnaptysBio	$234.60 million	6.21	-$13.23 million	$5.37	9.07

AnaptysBio has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Summary

AnaptysBio beats Fractyl Health on 8 of the 11 factors compared between the two stocks.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.